February 21st, 2020
Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers.
Should I buy Novartis stock?You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. Trading strategies are meant for helping you in the decision process of what stocks to choose and when is the best moment to buy them. At Stocks2.com, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
Currently, Novartis stock doesn't match any of these trading strategies, so our recommendation is not to buy.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Novartis stock a buy?
Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness.Unfortunately, we couldn't detect any rating for NVS stock for the last 30 days.
Novartis stock analysis
After reaching all time highs on February/12, Novartis inched 0.49% on February 21st to $96.76.
After reaching all time highs on Feb 12th, Novartis inched 0.49% to $96.76. NVS shows a short term strength with several rising tops and rising bottoms. In the very short term, on Thursday it marked a new bottom at $95.88 that should act a support if Novartis starts a trading flat base in the range of $95.88 - $99.84 Trading the long side, we should wait to a new breakout over $99.84 to find the next buy point. On December, SMA50d and SMA100d crossed up triggering a rise of 3.98%. Since last November when NVS stock price broke up the SMA100d line, it gained $8.13 (9.17%). On February 12th, NVS hit a new all time high, pushing higher than on February 11th tops. Check different trading setups that use ATHs as triggers.
Novartis shares slightly fell -0.89% this week, ending at $96.76.
Novartis stock is trading in the range of its last top and last bottom. Loosing would mean breaking the current uptrend. Breakdowns under last bottom are selling point signals for some trading strategies. Not so far away is the last all-time high Novartis marked last week. Since early December 2019 when SMA10w and SMA20w crossed up, NVS price gained $4.69 per share (5.09%). Since mid November 2019 when NVS stock price broke up the SMA20w line, it gained $8.39 (9.49%).
Novartis stock price history
Novartis IPO was on November 7th, 1996 at $12.78 per share1. Since then, NVS stock surged a 657.10%, with a yearly average of 28.60%. If you had invested right after NVS's IPO a $1,000 in Novartis stock in 1996, it would worth $6,571.00 today.
1: Adjusted price after possible price splits or reverse-splits.
Novartis stock historical price chart
NVS stock reached all-time highs on Feb/12 with a price of $99.84.
Novartis stock price targetPredicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. For the last month we have not found any price target for Novartis stock by any trusted analyst.
Financials and fundamental analysis
Earnings date and Earnings per ShareNovartis disappointed analysts when it reported an Earnings per Share (EPS) of $1.24 when the market consensus was $1.33.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2017, last anual sales report draw a shining gain of 6.05% to $53,166.00 million dollars. When comparing 2018 vs 2017, instead, profit margin (that is, the net income divided by revenues) jumped a 8.36% to 23.72%.
|2013||$48,290 M||-||$8,520 M17.6%||-|
|2014||$53,634 M||11.07%||$10,210 M19.0%||19.84%|
|2015||$50,387 M||-6.05%||$17,783 M35.3%||74.17%|
|2016||$49,436 M||-1.89%||$6,712 M13.6%||-62.26%|
|2017||$50,135 M||1.41%||$7,703 M15.4%||14.76%|
|2018||$53,166 M||6.05%||$12,611 M23.7%||63.72%|
Quarterly financial resultsNovartis reported $13,664.00 million in sales for 2018-Q4, a 4.14% up compared to previous quarter. Reported quarter income marked $1,195.00 M with a profit margin of 8.75%. Profit margin declined a -3.62% compared to previous quarter when profit margin was 12.37%. When comparing turnover to same quarter last year, Novartis sales marked a good growth and stepped up a 3.80%.
|2017-Q2||$12,050 M||-||$1,950 M16.2%||-|
|2017-Q3||$11,950 M||-0.83%||$2,000 M16.7%||2.56%|
|2017-Q4||$13,164 M||10.16%||$1,976 M15.0%||-1.20%|
|2018-Q1||$12,929 M||-1.79%||$2,025 M15.7%||2.48%|
|2018-Q2||$13,452 M||4.05%||$7,768 M57.7%||283.60%|
|2018-Q3||$13,121 M||-2.46%||$1,623 M12.4%||-79.11%|
|2018-Q4||$13,664 M||4.14%||$1,195 M8.7%||-26.37%|
|2019-Q1||$11,455 M||-16.17%||$1,766 M15.4%||47.78%|
Novartis ownershipWhen you are planning to invest in shares of a stock, it's worth to review its ownership structure.
Novartis shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 0.00% of all shares.
In case of Novartis stock, 11.34% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for NVS stock account 0.00%, no big difference from last month.
For a better understanding, the next table shows ownership data compared to other related companies:
|Market cap||$219.6 B|
|Total shares||2,270.0 M|
|Float shares||2,120.0 M|
|- Institutional holdings (%)||11.3%|
|- Insider holdings (%)||0.0%|
|Shares in short selling||0.0%|
|Friday, February 21st, 2020|
|Day range||$95.97 - $96.96|
|Average true range||$1.10|
|50d mov avg||$95.13|
|100d mov avg||$91.77|
|200d mov avg||$90.26|
Novartis performanceTo measure stock performance is always good to compare with competitors or related stocks. In the following table, we compare Novartis to :
Novartis competitorsUnfortunately, we could not find any public company that could be defined as Novartis competitor. This doesn't mean Novartis does not have any competitor in the market, it's just we could not detected it.
Latest Novartis stock news
- Seeking AlphaNovartis' Accelerated Review Sets Up A Potential Catalyst For FDA ApprovalJuly 25, 2019
- Seeking AlphaNovartis: A Transformation Story Not To Miss In 2019June 28, 2019
- Seeking AlphaNovartis Makes Substantial Pipeline Progress On A Couple Of FrontsJune 13, 2019
- Seeking AlphaNovartis Kisqali Might Have A Path Forward To Take On Pfizer's IbranceJune 11, 2019
- Seeking AlphaNovartis And Axovant Might Jointly Be Holding The Most Promising Neurodegeneration Drug In DevelopmentJune 4, 2019